<DOC>
	<DOCNO>NCT02100085</DOCNO>
	<brief_summary>This study follow change immune response measure HPV type 16/18 E6 E7 specific T cell response lesion condition subject administer DNA-based therapeutic vaccine .</brief_summary>
	<brief_title>Safety Efficacy GX-188E DNA Therapeutic Vaccine Administered Electroporation After Observation</brief_title>
	<detailed_description>This follow-up study investigate change immunogenicity lesion condition subject cervical intraepithelial neoplasia ( CIN ) 3 enrol complete GX-188E phase I study . Subjects make visit week 48 ( V1 ) week 228 ( V8 ) every 6 month final administration GX-188E . The endpoint evaluate change immune response , involve lesion infection status compare final visit phase I study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<criteria>Female age 20 50 ( inclusive ) The subject visit within 48 week final injection GX188E Those voluntarily sign informed consent form Prior participation clinical trial within 30 day prior visit 1 Any ineligible condition discretion investigator would ineligible participate study</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Phase 1 follow</keyword>
	<keyword>Cervical Intraepithelial Neoplasia</keyword>
	<keyword>Adult</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
</DOC>